Alkermes To Participate In The Bofa Securities 2022 Biotech ...| MENAFN.COM

Thursday, 02 February 2023 02:09 GMT

Alkermes To Participate In The Bofa Securities 2022 Biotech SMID Cap Conference'


(MENAFN- PR Newswire)

DUBLIN, Nov. 30, 2022 /PRNewswire/ -- alkermes plc (Nasdaq: alks ) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast may
be accessed under the Investors tab on
and will be archived for 14 days.

About Alkermes plc

Alkermes plc
is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in
Dublin, Ireland,
Alkermes has a research and development center in
Waltham,
Massachusetts; a research and manufacturing facility in Athlone,
Ireland; and a manufacturing facility in
Wilmington,
Ohio. For more information, please visit Alkermes'
website at
.

Contact:Sandy CoombsInvestor Relations+1 781 609 6377

SOURCE Alkermes plc

MENAFN30112022003732001241ID1105252234


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.